Service of the U.S. National Institutes of Health					
	Trial re	ecord 3 of 12 for: cerebral palsy and umbilical cord			
	Pro	evious Study Return to List Next Study			
mbilical Cord B	lood Therapy for Ch	nildren With Cerebral Palsy			
This study has bee Sponsor:	n completed.	ClinicalTrials.gov Identifier: NCT01639404			
Sponsor: MinYoung Kim, M.E).				
Sponsor: MinYoung Kim, M.E Information provided		NCT01639404 First received: July 10, 2012			

Purpose

This study aims to evaluate the efficacy of umbilical cord blood therapy for children with cerebral palsy.

Condition	Intervention
Cerebral Palsy	Procedure: Umbilical Cord Blood Administration Other: Active Rehabilitation

Study Type: Study Design:	Interventional Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment
	Masking: Open Label Primary Purpose: Treatment

Official Title: Allogeneic Umbilical Cord Blood Therapy for Children With Cerebral Palsy

Resource links provided by NLM:

MedlinePlus related topics: Cerebral Palsy Paralysis Rehabilitation

U.S. FDA Resources

Further study details as provided by Bundang CHA Hospital:

Primary Outcome Measures:

· Changes in Motor Performance [Time Frame: Baseline - 1 month - 3 months] [Designated as safety issue: No]

GMPM (Gross Motor Performance Measure) as a standardized measurement tool for assessing quality of movement regarding 3 properties of 5 ones; alignment, coordination, dissociated movement, stability, and weight shift (range: 0~100, Higher value means better motor quality). GMPM scores at each assessment time points will be reported.

Changes in Standardized Gross Motor Function [Time Frame: Baseline - 1 month - 3 months] [Designated as safety issue: No]

GMFM (Gross Motor Function Measure) as a standardized measurement tool for assessing Gross Motor Function consisting of sub-scales; lying & rolling, sitting, crawling & kneeling, standing, walking, running & jumping (range: 0~100, Higher value means better gross motor function). GMFM scores at each assessment time points will be reported.

Secondary Outcome Measures:

· Changes in Cognitive Neurodevelopmental Outcome [Time Frame: Baseline - 1 month - 3 months] [Designated as safety issue: No]

Umbilical Cord Blood Therapy for Children With Cerebral Palsy - Full Text View - Clinical Trials.gov

Korean version of Bayley Scale of Infant Development-II (K-BSID-II) Mental Scales (higher value means better mental function: 0 - worst, 178 - best). K-BSID-II Mental Scale raw scores at each assessment time points will be reported.

· Changes in Motor Neurodevelopmental Outcome [Time Frame: Baseline - 1 month - 3 months] [Designated as safety issue: No]

Korean version of Bayley Scale of Infant Development-II (K-BSID-II) Motor Scales (higher value means better motor function: 0 - worst, 112 - best). K-BSID-II Motor Scale raw scores at each assessment time points will be reported.

• Changes in Functional Independence in Daily Activities [Time Frame: Baseline - 1 month - 3 months] [Designated as safety issue: No]

WeeFIM (Functional Independence Measure for Children) measures functional independence in daily activities. WeeFIM contains 18 items and each item is ranked from complete dependence (scored as 1) to complete independence (scored as 7). The range is from 18 to 126 and higher scores mean more independent performance in daily activities. Total WeeFIM scores measured at each assessment time points will be reported.

· Changes in Visual Perception Test [Time Frame: Baseline - 1 month - 3 months] [Designated as safety issue: No]

Visual perception function will be evaluated with one of three measures: DTVP (Developmental Test of Visual Perception), MVPT (Motor-free Visual Perception Test), and VMI (Visual-Motor Integration, Visual Perception and Motor Coordination). All can be scored as percentile rank from 0 to 100. Higher values mean better visual perception ability.

· Changes in Muscle Strength [Time Frame: Baseline - 1 month - 3 months] [Designated as safety issue: No]

Summation of MMT (manual muscle strength test score): summated scores of the manual muscle strength test (zero=0, trace=1, poor=2, fair=3, good=4, normal=5) for flexors, extensors, abductors, and adductors of bilateral shoulder and hip joints; flexors and extensors of bilateral elbow, wrist, and knee; dorsiflexors and plantar flexors of the ankles (range: 0 ~ 160) Higher scores mean better muscle strength. Categories of outcome table will be summation of MMT scores measured at each assessment time point.

· Changes in Functional Performance in Daily Activities [Time Frame: Baseline - 1 month - 3 months] [Designated as safety issue: No]

Pediatric Evaluation of Disability Inventory (PEDI) for assessing functional performance in daily activities in children (All values are adjusted and higher value means better functional performance, 0 - worst, 100 - best). We will report 2 scales and 3 domains of each scale: a Functional Skill Scale (FSS) and a Caregiver Assistance Scale (CAS) which are divided respectively into 3 domains: self care, mobility, and social function. Categories of outcome table will be each domain scores measured at each assessment time point.

Enrollment:	17
Study Start Date:	July 2012
Study Completion Date:	March 2013
Primary Completion Date:	March 2013 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Umbilical Cord Blood and Rehabilitation Allogeneic Umbilical Cord Blood Administration and Active Rehabilitation	Procedure: Umbilical Cord Blood Administration The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression. Other Name: Donated Umbilical Cord Blood Units from Affiliated Cord Blood Bank Other: Active Rehabilitation All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.

Detailed Description:

Cerebral palsy is a disorder of movement and posture resulted from a non-progressive lesion or injury of the immature brain. It is a leading cause of childhood onset disability.

Many experimental animal studies have revealed that umbilical cord blood is useful to repair neurological injury in brain.

On the basis of many experimental studies, umbilical cord blood is suggested as a potential therapy for cerebral palsy.

Eligibility

Ages Eligible for Study:6 Months to 20 YearsGenders Eligible for Study:BothAccepts Healthy Volunteers:No

Criteria

9/24/13

Inclusion Criteria:

- · Cerebral Palsy with abnormal muscle tone
- Gross Motor Function Classification System (GMFCS): I, II, III, IV, V
- · Willing to comply with all study procedure

Exclusion Criteria:

- · Medical illnesses including pneumonia or renal function at enrollment
- · Presence of known genetic disease
- · Presence of drug hypersensitivity which is related to this study remedy
- · Poor cooperation of guardian, including inactive attitude for rehabilitation and visits for follow-up
- · Decision by the principal investigator when there are unexpected events that may affect the outcomes

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01639404

Locations

Korea, Republic of

CHA Bundang Medical Center, CHA University Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-712

Sponsors and Collaborators

MinYoung Kim, M.D.

Investigators

Principal Investigator: MinYoung Kim, M.D., Ph.D. CHA Bundang Medical center, CHA university

More Information

No publications provided

Responsible Party:MinYoung Kim, M.D., Associate Professor, Bundang CHA HospitalClinicalTrials.gov Identifier:NCT01639404History of ChangesOther Study ID Numbers:CPUCBStudy First Received:July 10, 2012Last Updated:August 8, 2013Health Authority:Korea: Institutional Review Board

Keywords provided by Bundang CHA Hospital: Cerebral Palsy Umbilical Cord Blood Rehabilitation

Additional relevant MeSH terms: Cerebral Palsy Paralysis Brain Damage, Chronic Brain Diseases

Central Nervous System Diseases Nervous System Diseases Neurologic Manifestations Signs and Symptoms

ClinicalTrials.gov processed this record on September 22, 2013